Kader Yagiz, Ph.D.
Affiliations: | 2006 | Purdue University, West Lafayette, IN, United States |
Area:
Nutrition, Molecular BiologyGoogle:
"Kader Yagiz"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Dorothy M. Morre | grad student | 2006 | Purdue | |
| (A transgenic mouse line overexpressing the anticancer green tea target, tNOX, responds to EGCg.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Mitchell LA, Yagiz K, Hofacre A, et al. (2019) PD-L1 checkpoint blockade delivered by retroviral replicating vector confers anti-tumor efficacy in murine tumor models. Oncotarget. 10: 2252-2269 |
| Yagiz K, Rodriguez-Aguirre ME, Lopez Espinoza F, et al. (2018) A Retroviral Replicating Vector Encoding Cytosine Deaminase and 5-FC Induces Immune Memory in Metastatic Colorectal Cancer Models. Molecular Therapy Oncolytics. 8: 14-26 |
| Mohanty SK, Yagiz K, Pradhan D, et al. (2017) STAT3 and STAT5A are potential therapeutic targets in castration-resistant prostate cancer. Oncotarget. 8: 85997-86010 |
| Ready D, Yagiz K, Amin P, et al. (2017) Mapping the STK4/Hippo signaling network in prostate cancer cell. Plos One. 12: e0184590 |
| Mohanty SK, Yagiz K, Luthringer L, et al. (2017) Abstract 5707: STAT3 and STAT5a are potential therapeutic targets in castration-resistant prostate cancer Cancer Research. 77: 5707-5707 |
| Jolly D, Mitchell L, Yagiz K, et al. (2017) Tmic-42. Toca 511 And 5-Fc Induces T Cell-Mediated Antitumor Immunity In A Mouse Glioma Model Which Is Enhanced By The Addition Of A Therapeutic Antibody Against Ctla-4 And Correlative With A Reduction In Memory T Regulatory Cells. Neuro-Oncology. 19 |
| Yagiz K, Huang TT, Lopez Espinoza F, et al. (2016) Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models. Neuro-Oncology |
| Mitchell L, Espinoza FL, Yagiz K, et al. (2016) Abstract 3212: Combining Toca 511 and 5-fluorocytosine with αPD-1 or αCTLA-4 antibody significantly reduces tumor burden compared to either checkpoint inhibitor alone or in combination in a subcutaneous mouse glioma model Cancer Research. 76: 3212-3212 |
| Rodriguez-Aguirre M, Yagiz K, Espinoza FL, et al. (2016) Abstract 1413: Treatment of mouse liver and brain colon cancer metastases with Toca 511 and 5-fluorocytosine for intratumoral production of 5-fluorouracil leads to increased survival, induction of antitumor immune responses, and reduction of MDSC Cancer Research. 76: 1413-1413 |
| Mitchell L, Yagiz K. (2016) Imst-01. Combining Toca 511 And 5-Fluorocytosine With Checkpoint Inhibitors Significantly Reduced Tumor Burden In A Mouse Model Of Glioma Neuro-Oncology. 18 |